[Explanation] On March 17, the State Council ’s joint prevention and control mechanism held a press conference in Beijing to introduce the latest development of drug vaccines and testing reagents.
[Explanation] Wang Junzhi, an academician of the Chinese Academy of Engineering, introduced the development of the new crown virus vaccine. At present, China is conducting emergency research and development in accordance with 5 technical routes, and most of the research and development teams can complete preclinical research in April.
[Contemporary] Wang Junzhi, Academician of Chinese Academy of Engineering
The first nine tasks identified have completed most of the pre-clinical research and development work, including animal effectiveness and safety studies. It is expected that most of the research and development teams will complete pre-clinical preparations in April, and Clinical applications and clinical trials have started one after another.
[Explanation] Wang Junzhi said that some units that have made rapid progress in research and development have submitted application materials and can start clinical trials after approval. He believes that the development of China's new crown virus vaccine is in the forefront of international development.
[Contemporary] Wang Junzhi, Academician of Chinese Academy of Engineering
In China, there are units that have made rapid progress in research and development. They have submitted clinical trial application materials to the State Food and Drug Administration, and have already started clinical trial program demonstration and recruitment of volunteers. After the State Food and Drug Administration has examined and approved in accordance with relevant laws and regulations, clinical trials will begin. It should be said that the development of China's new crown vaccine is generally internationally advanced and will not be slower than abroad.
[Explanation] Speaking of new crown pneumonia treatment drugs, Zhang Xinmin, director of the Biological Center of the Ministry of Science and Technology, introduced that for the treatment of light and ordinary patients, the focus is on promoting chloroquine phosphate, fapilavir and traditional Chinese medicine; for the treatment of severe and critical patients, Promote the clinical application of recovery plasma, tocilizumab, stem cells and artificial liver.
[Concurrent] Zhang Xinmin, Director of the Biological Center of the Ministry of Science and Technology
Among them, Fapilavir has completed clinical research and has shown good clinical efficacy. In terms of safety, Fapilavir was approved for listing in Japan in 2014, and no obvious adverse reactions have been seen since listing. No clinically significant adverse reactions have been found in the clinical studies of neocoronary pneumonia.
[Explanation] When talking about stem cell therapy, Zhang Xinmin said that stem cell is safe and effective in treating patients with new coronary pneumonia.
[Concurrent] Zhang Xinmin, Director of the Biological Center of the Ministry of Science and Technology
The clinical manifestations, respiratory function, and imaging examinations have all improved. Generally, cure levels can be reached in 8-10 days. In addition, the role of stem cells in blocking pulmonary fibrosis and promoting lung injury repair has shown that it has unique advantages in preventing pulmonary fibrosis and improving the long-term prognosis of patients.
[Explanation] Zhang Xinmin said that the scientific research group will further promote the application of the research results in Wuhan and launch a Chinese plan for drug treatment in response to the current international epidemic situation.
[Concurrent] Zhang Xinmin, Director of the Biological Center of the Ministry of Science and Technology
In terms of drug screening research and development, China has disclosed the new crown pneumonia diagnosis and treatment plan and drug screening results to the world. Fapilavir, recovery plasma, Chinese medicine and other key drugs have been provided to some countries where epidemics have occurred. In vaccine development, we actively advocate global cooperation. At present, many companies or scientific research institutions in China have cooperated with foreign countries to promote the development of new crown vaccines.
Reporter Liu Chao reports from Beijing
Editor-in-chief: [Wang Kai]